Financing  ||| S:0 E:10 ||| VBG
the  ||| S:10 E:14 ||| DT
delivery  ||| S:14 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
vaccines  ||| S:26 E:35 ||| NNS
to  ||| S:35 E:38 ||| TO
children  ||| S:38 E:47 ||| NNS
and  ||| S:47 E:51 ||| CC
adolescents ||| S:51 E:62 ||| NNS
:  ||| S:62 E:64 ||| :
challenges  ||| S:64 E:75 ||| NNS
to  ||| S:75 E:78 ||| TO
the  ||| S:78 E:82 ||| DT
current  ||| S:82 E:90 ||| JJ
system  ||| S:90 E:97 ||| NN
Recent  ||| S:97 E:104 ||| JJ
increases  ||| S:104 E:114 ||| NNS
in  ||| S:114 E:117 ||| IN
the  ||| S:117 E:121 ||| DT
number  ||| S:121 E:128 ||| NN
and  ||| S:128 E:132 ||| CC
costs  ||| S:132 E:138 ||| NNS
of  ||| S:138 E:141 ||| IN
vaccines  ||| S:141 E:150 ||| NNS
routinely  ||| S:150 E:160 ||| RB
recommended  ||| S:160 E:172 ||| VBN
for  ||| S:172 E:176 ||| IN
children  ||| S:176 E:185 ||| NNS
and  ||| S:185 E:189 ||| CC
adolescents  ||| S:189 E:201 ||| NNS
have  ||| S:201 E:206 ||| VBP
raised  ||| S:206 E:213 ||| VBN
concerns  ||| S:213 E:222 ||| NNS
about  ||| S:222 E:228 ||| IN
the  ||| S:228 E:232 ||| DT
ability  ||| S:232 E:240 ||| NN
of  ||| S:240 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
current  ||| S:247 E:255 ||| JJ
vaccine  ||| S:255 E:263 ||| NN
financing  ||| S:263 E:273 ||| NN
and  ||| S:273 E:277 ||| CC
delivery  ||| S:277 E:286 ||| NN
systems  ||| S:286 E:294 ||| NNS
to  ||| S:294 E:297 ||| TO
maintain  ||| S:297 E:306 ||| VB
access  ||| S:306 E:313 ||| NN
to  ||| S:313 E:316 ||| TO
recommended  ||| S:316 E:328 ||| JJ
vaccines  ||| S:328 E:337 ||| NNS
without  ||| S:337 E:345 ||| IN
financial  ||| S:345 E:355 ||| JJ
barriers ||| S:355 E:363 ||| NNS
.  ||| S:363 E:365 ||| .
Here  ||| S:365 E:370 ||| RB
we  ||| S:370 E:373 ||| PRP
review  ||| S:373 E:380 ||| VB
the  ||| S:380 E:384 ||| DT
current  ||| S:384 E:392 ||| JJ
state  ||| S:392 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
US  ||| S:401 E:404 ||| NNP
financing  ||| S:404 E:414 ||| NN
for  ||| S:414 E:418 ||| IN
vaccine  ||| S:418 E:426 ||| NN
delivery  ||| S:426 E:435 ||| NN
to  ||| S:435 E:438 ||| TO
children  ||| S:438 E:447 ||| NNS
and  ||| S:447 E:451 ||| CC
adolescents  ||| S:451 E:463 ||| NNS
and  ||| S:463 E:467 ||| CC
identify  ||| S:467 E:476 ||| VB
challenges  ||| S:476 E:487 ||| NNS
that  ||| S:487 E:492 ||| WDT
should  ||| S:492 E:499 ||| MD
be  ||| S:499 E:502 ||| VB
addressed  ||| S:502 E:512 ||| VBN
to  ||| S:512 E:515 ||| TO
ensure  ||| S:515 E:522 ||| VB
future  ||| S:522 E:529 ||| JJ
access  ||| S:529 E:536 ||| NN
to  ||| S:536 E:539 ||| TO
routinely  ||| S:539 E:549 ||| RB
recommended  ||| S:549 E:561 ||| VBN
vaccines  ||| S:561 E:570 ||| NNS
without  ||| S:570 E:578 ||| IN
financial  ||| S:578 E:588 ||| JJ
barriers ||| S:588 E:596 ||| NNS
.  ||| S:596 E:598 ||| .
Challenges  ||| S:598 E:609 ||| NNS
were  ||| S:609 E:614 ||| VBD
considered  ||| S:614 E:625 ||| VBN
from  ||| S:625 E:630 ||| IN
the  ||| S:630 E:634 ||| DT
perspectives  ||| S:634 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
vaccine  ||| S:650 E:658 ||| NN
providers ||| S:658 E:667 ||| NNS
;  ||| S:667 E:669 ||| :
state  ||| S:669 E:675 ||| NN
and  ||| S:675 E:679 ||| CC
local  ||| S:679 E:685 ||| JJ
governments ||| S:685 E:696 ||| NNS
;  ||| S:696 E:698 ||| :
insurers ||| S:698 E:706 ||| NNS
,  ||| S:706 E:708 ||| ,
employers ||| S:708 E:717 ||| NNS
,  ||| S:717 E:719 ||| ,
and  ||| S:719 E:723 ||| CC
other  ||| S:723 E:729 ||| JJ
health  ||| S:729 E:736 ||| NN
care  ||| S:736 E:741 ||| NN
purchasers ||| S:741 E:751 ||| NNS
;  ||| S:751 E:753 ||| :
vaccine  ||| S:753 E:761 ||| NN
manufacturers ||| S:761 E:774 ||| NNS
;  ||| S:774 E:776 ||| :
and  ||| S:776 E:780 ||| CC
consumers ||| S:780 E:789 ||| NNS
.  ||| S:789 E:791 ||| .
